CX Institutional
CRL icon

CX Institutional’s Charles River Laboratories CRL Stock Holding History

CX Institutional’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$410K Buy
1,389
+5
+0.4% +$1.32K 0.01% 524
2026
Q2 		$314K Sell
1,384
-901
-39% -$160K 0.01% 609
2026
Q1 		$394K Sell
2,285
-57
-2% -$10.6K 0.01% 520
2025
Q4 		$467K Sell
2,342
-1,982
-46% -$360K 0.01% 440
2025
Q3 		$677K Sell
4,324
-27
-0.6% -$4.29K 0.02% 362
2025
Q2 		$660K Buy
4,351
+1,232
+39% +$164K 0.02% 320
2025
Q1 		$469K Sell
3,119
-113
-3% -$18.9K 0.02% 381
2024
Q4 		$597K Sell
3,232
-112
-3% -$21.6K 0.02% 319
2024
Q3 		$659K Sell
3,344
-154
-4% -$32K 0.03% 337
2024
Q2 		$723K Sell
3,498
-1
-0% -$227 0.03% 322
2024
Q1 		$948K Buy
3,499
+20
+0.6% +$4.78K 0.05% 288
2023
Q4 		$822K Buy
3,479
+133
+4% +$26.2K 0.04% 282
2023
Q3 		$656K Buy
3,346
+19
+0.6% +$3.9K 0.04% 297
2023
Q2 		$700K Buy
3,327
+170
+5% +$33.8K 0.04% 318
2023
Q1 		$632K Buy
3,157
+11
+0.3% +$2.49K 0.03% 331
2022
Q4 		$686K Buy
3,146
+38
+1% +$8.3K 0.04% 324
2022
Q3 		$612K Buy
3,108
+5
+0.2% +$1.08K 0.04% 316
2022
Q2 		$664K Sell
3,103
-7
-0.2% -$1.71K 0.05% 279
2022
Q1 		$883K Buy
3,110
+2
+0.1% +$617 0.07% 229
2021
Q4 		$1.17M Buy
3,108
+2
+0.1% +$777 0.09% 190
2021
Q3 		$1.28M Sell
3,106
-2
-0.1% -$831 0.1% 192
2021
Q2 		$1.15M Hold
3,108
– – 0.09% 197
2021
Q1 		$901K Hold
3,108
– – 0.08% 201
2020
Q4 		$777K Hold
3,108
– – 0.07% 213
2020
Q3 		$704K Buy
3,108
+1
+0% +$208 0.08% 189
2020
Q2 		$542K Buy
3,107
+7
+0.2% +$1.12K 0.07% 187
2020
Q1 		$391K Hold
3,100
– – 0.06% 191
2019
Q4 		$474K Hold
3,100
– – 0.08% 152
2019
Q3 		$410K Sell
3,100
-14
-0.4% -$1.88K 0.07% 173
2019
Q2 		$442K Buy
3,114
+14
+0.5% +$1.9K 0.07% 166
2019
Q1 		$450K Hold
3,100
– – 0.08% 162
2018
Q4 		$351K Buy
+3,100
New +$388K 0.07% 145

Other funds holding CRL

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Confluence Investment Management
Confluence Investment Management St. Louis, Missouri $5.97B AUM 5.11% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
Sendero Wealth Management
Sendero Wealth Management San Antonio, Texas $1B AUM 21.35% 1-Year Est. Return
PensionDanmark
PensionDanmark Copenhagen O, Denmark $12.3B AUM 33.99% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return
Mitchell & Pahl Private Wealth
Mitchell & Pahl Private Wealth Oklahoma City, Oklahoma $277M AUM 23.93% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

CX Institutional's CRL Position: Q3 2026 in Review

CX Institutional increased its Charles River Laboratories (CRL) stake by 0.36% in Q3 2026, buying an estimated $1.32K and bringing the position to 1,389 shares worth $410K. The position accounts for 0.01% of the portfolio, ranked #524.

CX Institutional first reported a position in CRL in Q4 2018 and has held it in 32 quarters since. The position peaked at $1.28M in Q3 2021. 76 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • CX Institutional held 1,389 shares of Charles River Laboratories worth $410K as of Q3 2026.
  • CX Institutional bought 5 Charles River Laboratories shares in Q3 2026, an estimated $1.32K.
  • Charles River Laboratories made up 0.01% of CX Institutional's portfolio in Q3 2026, its #524 holding.
  • CX Institutional first reported a position in Charles River Laboratories in Q4 2018 and has held it in 32 quarters since.
  • CX Institutional's Charles River Laboratories position peaked at $1.28M in Q3 2021.
  • 76 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.